ClinicalTrials.gg
RecruitingNCT06468358TRIGGERCD8Updated Sep 11, 2025

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of LB1410 and LB4330 in Solid Tumor, sponsored by L & L Bio Co., Ltd., Ningbo, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by L & L Bio Co., Ltd., Ningbo, China · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
194
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody,LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors.

Read the detailed description

The phase Ib/II clinical study in Chinese patients with advanced or metastatic solid tumors to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD), anti-tumor efficacy, and biomarkers of LB1410 in combination with LB4330.

The study will include 2 parts: dose escalation (Phase Ib) and dose expansion (Phase II). Repeated intravenous infusion of LB1410 in combination with LB4330 in patients with metastatic or advanced pancreatic ductal adenocarcinoma, cholangiocarcinoma, colorectal cancer, ovarian, fallopian tube, or primary peritoneal cancer, non-small cell lung cancer, gastric and gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, renal cell carcinoma, cervical squamous cell carcinoma, and endometrial carcinoma.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

L & L Bio Co., Ltd., Ningbo, China is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be ≥ 18 years of age when signing .
  2. (ECOG) performance status 0 or 1 without deterioration in the past 2 weeks.
  3. Estimated of ≥12 weeks.
  4. Baseline IL-6 levels below 40 pg/mL.
  5. or cytologically documented advanced and solid tumors for which can't tolerate standard treatment, standard treatment fails, or no standard treatment is available at this stage.
  6. Must have at least one according to (RECIST) v1.1 at screening.
  7. Adequate hematologic function prior to registration for protocol therapy defined as the following criteria:

    1. (ANC) ≥ 1.5 × 10\^9/L, without the use of granulocyte colony-stimulating factor such as filgrastim in the 2 weeks prior to study treatment (≤ 14 days);
    2. count ≥ 120 × 10\^9/L, without transfusion or use of drugs like recombinant human platelet growth factor in the 2 weeks prior to study treatment (≤ 14 days), for HCC patients, platelet count ≥ 100 × 10\^9/L;
    3. ≥ 90 g/L, without transfusion or use of drugs like erythropoietin in the 2 weeks prior to study treatment (≤ 14 days).
  8. Both and ALT ≤ 3 × (both AST and ALT \< 5 × ULN for subjects with known hepatocellular carcinoma or hepatic metastases); total ≤ 1.5 × ULN (except for subjects with elevated serum bilirubin due to documented underlying conditions such as Gilbert's syndrome or familial benign unconjugated hyperbilirubinemia); for bile duct cancer patients, total bilirubin ≤ 2 × ULN; and serum albumin ≥ 30 g/L.
  9. Adequate renal function defined as: serum creatinine ≤ 1.5 × ULN, and ≥ 50 mL/min (calculated by Cockcroft-Gault formula).
  10. Requirements for coagulation function are as follows:

    1. (aPTT) ≤ 1.5 × ULN;
    2. international normalized ratio (INR) ≤ 1.5 × ULN (INR ≤ 3 × ULN for subjects receiving warfarin anticoagulant therapy).
  11. Any prior anti-tumor therapies (including endocrine/chemotherapy/targeted therapy/immunotherapy) before treatment should washout:

    1. at least 4 weeks for biological therapy (e.g., antibodies);
    2. at least 2 weeks or 5 half-lives (whichever is longer) for small molecule drugs, including 5-FU or its derivatives; at least 6 weeks for nitrosoureas and mitomycin;
    3. at least 2 weeks for Chinese herbal medicine used for indications of anti-tumor activity;
    4. at least 4 weeks for any systemic therapeutic drugs;
    5. at least 2 weeks for any radiotherapy;
    6. any related toxicities or prior adverse events resolved to baseline or ≤ 5.0 grade 1 (excluding toxicities without safety risk judged by the investigator, such as alopecia, grade 2 peripheral neuropathy, stable hypothyroidism under hormone replacement therapy, etc.).
  12. Phase Ib dose escalation additional inclusion criteria: histologically or cytologically documented advanced malignant solid tumors (preferably pancreatic ductal adenocarcinoma, cholangiocarcinoma, ovarian cancer, microsatellite stable colorectal cancer, advanced solid tumors previously treated with /PD-L1 inhibitors, such as gastric or gastroesophageal junction adenocarcinoma, or other solid tumors determined by the investigator and sponsor);
  13. Phase II (phase IIa and IIb) dose expansion cohort A additional inclusion criteria:

    1. must have received at least one but no more than two ;
    2. CA199 \< 1000 IU/mL during screening period
    3. must not have received any immune checkpoint inhibitor (ICI) therapy.
  14. Phase II (phase IIa and IIb) dose expansion cohort B additional inclusion criteria:

    1. must have received at least one but no more than three prior lines of systemic therapy;
    2. without C-Met, FGFR, IDH1 mutations or the genotype is unknown;
    3. CA199 \< 1000 IU/mL during screening period.
  15. Phase II (phase IIa and IIb) dose expansion cohort C additional inclusion criteria:

    1. must have received at least one but no more than three prior lines of systemic therapy;
    2. CA199 \< 1000 IU/mL during screening period;
    3. must not have received any immune checkpoint inhibitor (ICI) therapy;
    4. KRAS, NRAS and BRAF are wild type;
    5. without hepatic metastasis.
  16. Phase II (phase IIa and IIb) dose expansion cohort D additional inclusion criteria:

    1. recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer;
    2. must have received at least one but no more than three prior lines of systemic therapy;
    3. must not have received any immune checkpoint inhibitor (ICI) therapy;
    4. PD-L1 positive;
    5. have received one prior treatment regime of platinum-based chemotherapy;
    6. subjects with BRCA germline mutation (gBRCA mut) should been treated with a polyADP ribose polymerase inhibitor (PARPi), such as Olaparib, Rucaparib, or Niraparib.
  17. Phase II (phase IIa and IIb) dose expansion cohort E additional inclusion criteria:

    1. includes non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, kidney carcinoma, cervical squamous cell carcinoma, and endometrial carcinoma;
    2. must have received at least one but no more than two prior lines of systemic therapy, of which only one prior line of therapy contained an anti-PD-1/PD-L1;
    3. subjects with PD-1/PD-L1 primary resistance are required to be known PD-L1 positive.

      For NSCLC,

      1. non-squamous NSCLC must have documented test results of EGFR mutation, ALK fusion and ROS1 fusions, and the above driver genes must be wild type;
      2. non-squamous NSCLC, if RET, MET, NTRK gene testing has been performed previously, the results must be wild type;
      3. squamous NSCLC, if EGFR, ALK fusion gene and ROS1 fusion gene testing has been performed previously, the results must be wild type.

      For ESCC,

      1. exclude a history of gastrointestinal perforation and/or fistula within 6 months prior to initial medication;
      2. after esophageal or tracheal stent implantation is excluded.

      For HCC

      1. Barcelona Clinic Liver Cancer (BCLC) stage C and stage B;
      2. liver function status (CP) class A and class B in good status(≤7 points);
      3. exclude: a) known fibrolamellar HCC, sarcomatiod HCC, intrahepatic cholangiocarcinoma, or mixed hepatocellular carcinoma and cholangiocarcinoma and other histological types; b) tumor thrombus intrudes into the main and branches of large blood vessels such as portal vein, superior mesenteric vein or inferior vena cava, and causes complications such as portal hypertension and jaundice, or has related clinical risks judged by the researchers to be unsuitable for participation in this study; c) local to regional treatment for the liver (i.e., transarterial chemoembolization, transcatheter embolization, hepatic arterial infusion, radiotherapy, radioembolization, or ablation) within 4 weeks prior to initial medication.

      For RCC Clear cell renal cell carcinoma with or without sarcomatoid components.

      For EC

      1. histopathology confirmed Stage III/IV epithelial endometrial carcinoma including endometrioid carcinoma, non-endometrioid carcinoma, and carcinosarcoma;
      2. non-known ER, PR positive endometrial cancer.

      Note: ± adjuvant therapy is considered as one of treatment line; maintenance treatment as part of the former first-line treatment.

      PD-L1 positive is defined as PDL1 TPS≥1%, IPS≥1% or CPS≥1.

  18. Non-pregnant women and willingness of female participants to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of after signing informed consent, during the study period, and within 6 months after the last medication.
  19. Fully understand the informed consent and sign voluntarily.
  20. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

exclusion criteria:

  1. Pregnancy, lactation, or breastfeeding.
  2. Any prior ≥ Grade 3 immune-related adverse events (irAEs) while receiving immunotherapy or any grade irAE leading to discontinuation in prior immunotherapy; or grade 4 myelosuppression during prior antitumor therapy.
  3. Known history of allergy or severe reactions to other monoclonal antibodies or intravenous immunoglobulins such as anti-PD1/ antibodies, TIM-3, interleukin-10, or any of its .
  4. Active disease or symptomatic history of autoimmune disease (including celiac disease) requiring pharmacological doses of systemic and/or . Exceptions include vitiligo, relieved asthma/atopic disease, type 1 diabetes or hypothyroidism treatable with alternative therapy and achieving clinical stability during screening, or any other autoimmune disease after discussion with the principal investigator and sponsor.
  5. Requirement for systemic corticosteroids (≥ 10 mg/day prednisone or equivalent) or other immunosuppressive therapy within 14 days prior to the planned first dose of study intervention. Inhalational or topical corticosteroids and adrenal replacement steroids (≤ 15 mg prednisone once daily equivalent) are allowed in the non-active autoimmune disease. Ophthalmic, nasal, inhaled, and intra-articular corticosteroids are allowed; short-term use of glucocorticoids for prophylactic treatment (e.g., prevention of contrast media allergy) is allowed.
  6. Any of the following prior treatments:

    1. major surgical procedure (e.g., laparotomy, thoracotomy, organ resection, etc.), severe trauma, etc. (Replacement of intravenous drip droppers is acceptable) within 4 weeks prior to first dose, or not recovered from prior surgery; surgery within 14 days prior to the first dose to improves tumor complications or reduces tumor risk (e.g., cervical cancer subjects undergoing nephrostomy or urethral stent placement); significant surgery planned within 30 days after the first dose (except for local surgeries such as placement of systemic ports, core needle , and prostate biopsy, provided the surgery is completed at least 24 hours before the first dose of study intervention);
    2. receipt of or live attenuated vaccine within 4 weeks prior to first dose of study intervention;
    3. use of modulating drugs within 14 days prior to first dose of study intervention, including but not limited to thymosin peptide, interleukin-2, interferon, etc.;
    4. history of allogeneic organ transplant, hematopoietic stem cell transplant, or bone marrow transplant.
  7. Prior use of drugs with the same mechanism of action as the study drug (e.g., anti-PD1 antibody in combination with anti-TIM3 antibody, PD1/TIM3 bispecific antibody, or IL-10-containing drug).
  8. Active infection including syphilis, (HBsAg positive and HBV-DNA > 200 IU/mL or 1000 cps/mL or HBV DNA above the lower limit of detection if the lower limit of the study center is above 200 IU/mL), (Patients with HCV antibody positive but HCV-RNA \< lower limit of the study center were admitted).
  9. History of other malignant tumors within the past 3 years.
  10. Subjects with meningeal , spinal cord compression, or symptomatic unstable or requiring steroids and/or antiepileptic drugs within 4 weeks before enrollment.
  11. Severe infection requiring systemic antibiotic therapy within 14 days prior to first dose, or active infection requiring systemic treatment.
  12. Uncontrolled or poorly controlled diabetes ( ≥ 7.5 at screening), asthma, , or other diseases that pose a risk to study participants.
  13. Any syncope or seizure within 28 days prior to first dose of the study intervention.
  14. Known gastric bleeding lesions or patients considered to be at high risk of gastric bleeding by the investigator.
  15. Known presence of diseases such as symptomatic irritable bowel syndrome (such as chronic nausea, persistent recurrent vomiting or diarrhea) and gastric bleeding or intestinal obstruction.
  16. Known history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

    1. uncontrolled cardiovascular diseases within 3 months before the study, including but not limited to congestive heart failure required treatment ( > II), uncontrolled hypertension (resting blood pressure ≥ 160/100 mmHg), uncontrolled arrhythmia;
    2. myocardial infarction, unstable angina, viral myocarditis, pericarditis, cerebrovascular accident, or other acute uncontrolled heart disease within the recent 6 months;
    3. : Female > 470 milliseconds (ms), Male QTcF > 450 ms (QTcF = QT/RR1/3), or congenital long QT syndrome;
    4. Echocardiographic assessment: (LVEF) ≤ 50% measured by multiple-gated acquisition (MUGA) or echocardiography.
  17. Known evidence of interstitial lung disease, symptomatic or may interfere with suspicious findings or management of drug-related pulmonary toxicity.
  18. Active tuberculosis (TB).
  19. Positive (HIV).
  20. Diseases involving the central nervous system (except for patients with prior brain metastases treated at least 4 weeks before first dose, clinically stable, and not requiring long-term corticosteroid therapy) or history of 5.0 Grade 3 or higher drug-related central nervous system toxicity.
  21. Venous/arterial thrombotic events occurred within 6 months, including cerebrovascular accidents (such as , cerebral hemorrhage, cerebral infarction such as lacunar infarcts), deep venous thrombosis, and pulmonary embolism.
  22. Uncontrolled pleural effusion, pericardial effusion, or ascites ( recurrence requiring additional intervention every 2 weeks or more frequently).
  23. History of severe psychiatric disorders, substance abuse, alcoholism, or drug abuse.
  24. Have experienced ≥ grade 3 infusion-related reactions to protein therapeutics.
  25. Any other disease (including severe medical or psychiatric conditions) or significant clinical laboratory abnormalities judged by the investigator to potentially affect subject safety, study integrity, or subject's willing in the study.
  26. All known MSI-H/dMMR patients.
  27. All known positive (IHC 3+ or IHC 2+, Fish amplification) patients.
  28. Urine protein ≥ 2+, and 24-hour urine protein quantification ≥ 1.0g.
Terms in these criteria, in plain language(43)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
194 participants (estimated)

Study arms

  • Experimental
    Phase Ib, Dose Escalation of LB1410 in combination with LB4330

    Up to 4 dose cohorts will be enrolled in the dose-escalation part with the standard 3+3 dose escalation algorithm approach.

    Drug: LB1410 · Drug: LB4330

  • Experimental
    Phase II, Expansion Cohorts of LB1410 in combination with LB4330

    This part includes IIa and IIb. Phase IIa will be enrolled subjects at the dose level with initial anti-tumor activity observed in Phase Ib, the numbers of patients enrolled in the phase IIa could be adjusted based on previously available safety and preliminary efficacy data; the dose level of the phase IIb is the RP2D dose level determined in the phase Ib. The planned expanded cohorts are as follows: Cohort A: pancreatic ductal adenocarcinoma; Cohort B: cholangiocarcinoma; Cohort C: colorectal cancer; Cohort D: recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; Cohort E: other solid tumors (non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, renal cell carcinoma, cervical squamous cell carcinoma, and endometrial carcinoma).

    Drug: LB1410 · Drug: LB4330

Interventions

  • DrugLB1410

    anti-PD-1/TIM3 bispecific antibody

  • DrugLB4330

    anti-claudin18.2/IL-10 fusion protein

06

What researchers measure

Primary outcomes

  1. Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)

    Incidence of treatment-emergent adverse events (TEAEs) and treatment-related adverse events reported per NCI-CTCAE v5.0

    Time frame: up to 60 days following last dose

  2. Incidence and severity of serious adverse events (SAEs) and other special interest (immune-related AEs)

    According to NCI-CTCAE v5.0

    Time frame: up to 60 days following last dose

  3. Incidence of Dose limiting toxicity (DLT)

    The DLT for this study is defined per CTCAE 5.0 and will be evaluated in the Cycle 1 of treatment in the dose escalation part. If dosing delay occurs, the DLT evaluation should be correspondingly extended to 14 days after the second dosing.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  4. Maximum tolerance toxicity (MTD) and recommended dose for Phase II (RP2D) definition

    MTD and RP2D based on the safety data collected during the dose escalation phase (Phase I)

    Time frame: up to 1 year

  5. Overall response rate (ORR)

    Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria over the total number of evaluable patients

    Time frame: From first participant until last participant assessment, an average of 8 months

  6. Disease control rate (DCR)

    Percentage of patients whose best overall response is either a Complete Response, a Partial Response or Stable Disease according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria over the total number of evaluable patients.

    Time frame: From first participant until last participant assessment, an average of 8 months

  7. Duration of overall Response (DoR) by RECIST version 1.1

    Time from the date of first documented response (CR or PR) to the date of first documented disease progression according to RECIST 1.1 criteria or the date of death due to underlying cancer.

    Time frame: From first participant until last participant assessment, an average of 8 months

  8. Progression Free Survival (PFS) by RECIST version 1.1

    Time from the first infusion of LB1410 and LB4330 to the date of first documented tumor progression according to RECIST 1.1 criteria or death due to any cause, whichever occurs first over evaluable patients.

    Time frame: From first participant until last participant assessment, an average of 8 months

  9. DDC

    Time from the date of first documented CR, PR or SD to the date of first documented disease progression according to RECIST 1.1 criteria or the date of death due to any cause.

    Time frame: From first participant until last participant assessment, an average of 8 months

  10. Overall Survival (OS) duration

    Time from first LB1410 and LB4330 infusion to the date of death due to any cause over evaluable patients.

    Time frame: From first participant until last participant assessment, an average of 1 year

Secondary outcomes

  1. Pharmacokinetics of LB1410 and LB4330: Maximum plasma concentration of the study drug (Cmax)

    Maximum observed plasma concentration of the study drug

    Time frame: Through study completion, an average of 1 year

  2. Pharmacokinetics of LB1410 and LB4330: Area Under the concentration-time curve (AUC)

    Area under the plasma concentration-time curve

    Time frame: Through study completion, an average of 1 year

  3. Pharmacokinetics of LB1410 and LB4330: Clearance

    A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time

    Time frame: Through study completion, an average of 1 year

  4. Pharmacokinetics of LB1410 and LB4330: Terminal elimination half-life ( T½)

    Terminal elimination half life

    Time frame: Through study completion, an average of 1 year

  5. Evaluation of immunogenicity of each antibody drug in the combinations

    Occurrence of anti-drug antibody (ADA) measured in serum at selected time points during the study

    Time frame: Up to 60 days following last dose

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 21, 2024
StartActual
Jun 19, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06468358
Lead sponsor
L & L Bio Co., Ltd., Ningbo, China
Collaborators
Shanghai East Hospital
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Jun 19, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Sep 11, 2025

Study contacts

Yan Luan
Contact
luanyn2@lnlbio.com
+86-21-54152522
Caicun Zhou
Contact
Caicun Zhou
principal investigator · Shanghai East Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410

Start the discussion